US vaccine aversion a headwind for CSL
Vaccine aversion in the US has put a hole in CSL revenues in the first half, with the company saying the flu season is shaping up to be the worst in 15 to 20 years.
Vaccine aversion in the US has put a hole in CSL revenues in the first half, with the company saying the flu season is shaping up to be the worst in 15 to 20 years.
The US’s proposed imposition of blanket tariffs on steel and aluminium would result in an influx of steel dumped into the Australian market, experts say.
The promise of sweeping steep steel tariffs is set to deliver the first big test for Anthony Albanese’s relationship with the White House in the Trump 2.0 era.
A $US550m debt default at GFG Alliance company InfraBuild could be triggered if the company doesn’t file its already-delayed financial accounts before the end of March.
An AI chatbot named Lucy has become Barefoot’s go-to for advice, insights, and road trip conversations. Is this the beginning of a beautiful relationship or will it end in tears?
Property giant Lendlease has revealed it’s selling its interest in Capella Capital, a name behind major infrastructure projects such as Melbourne Metro tunnel, to the Sojitz Corporation.
More than four million Bupa customers can continue to use Healthscope hospitals with no gap fee after the companies ended a months-long stand off. But others aren’t so lucky.
ResMed’s competitors might be hamstrung by potential tariffs imposed by the US, boss Mick Farrell says, but adds the company, which delivered a strong quarterly, doesn’t need the help.
Silicon Valley owes its longevity to its ability to pivot and China’s new AI start-up could set it moving in a new direction.
The challenges faced by the electricity grid have been thrown into sharp relief as record solar output fails to offset coal outages and a lack of interconnection, driving spot prices higher.
Australian winemakers are sitting on a glut of mainly red but the reopening of the post-tariff Chinese market has helped ease the pressure by lifting exports 34 per cent in 2024.
There’s no reason Chemist Warehouse’s strong growth won’t continue, the Sigma Healthcare chair says, as the $34bn merger of the two companies passes a crucial vote.
Investors in a luxury tower at Queens Wharf have been refunded millions of dollars in deposits, with interest, after the developer confirmed the project faces three-year delays.
Australian retail supremo Solomon Lew had a first-hand view of how the now two-time US President tackled business deals and it offers plenty of lessons for leaders.
Original URL: https://www.ntnews.com.au/business/victoria-business/page/4